MedTrace Logo

Unboosted Atazanavir as Initial ART Therapy in China

NCT01459575 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2011-10-25

No results posted yet for this study

Summary

This is an open-label, Pilot study.The study hypothesis is that the feasibility and efficacy of a non-boosted ATV based HAART will be well as the first line treatment in a Chinese resource-limited setting.

Conditions

  • Antiretroviral Therapy

Sponsors & Collaborators

  • BMS company

    collaborator UNKNOWN

  • National Center for AIDS/STD Control and Prevention, China CDC

    lead OTHER_GOV

Principal Investigators

  • Fujie Zhang, MD · National Center for AIDS/STD control and prevention

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2005-12-31
Completion
2006-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459575 on ClinicalTrials.gov